parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituicytes/fscs	0.75
chemistry Open Targets	compounds already reach it: kbp5209, afatinib dimaleate, vandetanib +12	1.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	27 Parkinson's papers of 2,524	0.56
pathways Reactome	20 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 6442

receipt 6450: ERBB4 in dopamine neurons, braak

power: full sample +0.33 (p 0.188, n 18), 95% CI -0.17 to +0.69. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.30 (p 0.221, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.132, n 18). could be the mix.
skeptic: leave-one-out range +0.27 to +0.52, sign flips 0; without severely affected donors +0.33 (p 0.188, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ERBB4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6449: ERBB4 in astrocytes, braak

power: full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.06 (p 0.800, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.10, sign flips 7; without severely affected donors +0.00 (p 0.990, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ERBB4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts